Shanghai RAAS Blood Products Co Ltd Class A (SHE:002252) — Market Cap & Net Worth
Market Cap & Net Worth: Shanghai RAAS Blood Products Co Ltd Class A (002252)
Shanghai RAAS Blood Products Co Ltd Class A (SHE:002252) has a market capitalization of $5.40 Billion (CN¥36.91 Billion) as of May 2, 2026. Listed on the SHE stock exchange, this China-based company holds position #3402 globally and #515 in its home market, demonstrating a -1.24% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shanghai RAAS Blood Products Co Ltd Class A's stock price CN¥5.56 by its total outstanding shares 6637984837 (6.64 Billion). Analyse 002252 cash generation efficiency to see how efficiently the company converts income to cash.
Shanghai RAAS Blood Products Co Ltd Class A Market Cap History: 2015 to 2026
Shanghai RAAS Blood Products Co Ltd Class A's market capitalization history from 2015 to 2026. Data shows change from $20.91 Billion to $5.40 Billion (-12.56% CAGR).
Shanghai RAAS Blood Products Co Ltd Class A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shanghai RAAS Blood Products Co Ltd Class A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.86x
Shanghai RAAS Blood Products Co Ltd Class A's market cap is 0.86 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.20x
Shanghai RAAS Blood Products Co Ltd Class A's market cap is 3.20 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $20.91 Billion | $2.01 Billion | $1.44 Billion | 10.38x | 14.49x |
| 2016 | $21.88 Billion | $2.33 Billion | $1.61 Billion | 9.40x | 13.56x |
| 2017 | $18.84 Billion | $1.93 Billion | $835.83 Million | 9.77x | 22.54x |
| 2018 | $7.61 Billion | $1.80 Billion | -$1.52 Billion | 4.22x | N/A |
| 2019 | $7.05 Billion | $2.58 Billion | $607.89 Million | 2.73x | 11.59x |
| 2020 | $7.03 Billion | $2.76 Billion | $1.32 Billion | 2.55x | 5.31x |
| 2021 | $6.50 Billion | $4.29 Billion | $1.29 Billion | 1.52x | 5.02x |
| 2022 | $6.08 Billion | $6.57 Billion | $1.88 Billion | 0.93x | 3.23x |
| 2023 | $7.70 Billion | $7.96 Billion | $1.78 Billion | 0.97x | 4.33x |
| 2024 | $7.01 Billion | $8.18 Billion | $2.19 Billion | 0.86x | 3.20x |
Competitor Companies of 002252 by Market Capitalization
Companies near Shanghai RAAS Blood Products Co Ltd Class A in the global market cap rankings as of May 2, 2026.
Key companies related to Shanghai RAAS Blood Products Co Ltd Class A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Shanghai RAAS Blood Products Co Ltd Class A Historical Marketcap From 2015 to 2026
Between 2015 and today, Shanghai RAAS Blood Products Co Ltd Class A's market cap moved from $20.91 Billion to $ 5.40 Billion, with a yearly change of -12.56%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥5.40 Billion | -12.30% |
| 2025 | CN¥6.16 Billion | -12.19% |
| 2024 | CN¥7.01 Billion | -8.91% |
| 2023 | CN¥7.70 Billion | +26.72% |
| 2022 | CN¥6.08 Billion | -6.60% |
| 2021 | CN¥6.50 Billion | -7.53% |
| 2020 | CN¥7.03 Billion | -0.18% |
| 2019 | CN¥7.05 Billion | -7.37% |
| 2018 | CN¥7.61 Billion | -59.61% |
| 2017 | CN¥18.84 Billion | -13.90% |
| 2016 | CN¥21.88 Billion | +4.65% |
| 2015 | CN¥20.91 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Shanghai RAAS Blood Products Co Ltd Class A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.40 Billion USD |
| MoneyControl | $5.40 Billion USD |
| MarketWatch | $5.40 Billion USD |
| marketcap.company | $5.40 Billion USD |
| Reuters | $5.40 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shanghai RAAS Blood Products Co Ltd Class A
Shanghai RAAS Blood Products Co., Ltd. engages in the manufacture and sale of blood products in China. It offers human serum albumin, human intravenous immunoglobulin, human coagulation factor VIII, human prothrombin complex, human fibrinogen, human thrombin and human fibrin adhesive, human immunoglobulin, hepatitis B immunoglobulin, tetanus immunoglobulin, and rabies immunoglobulin products. The… Read more